Related Experiment Video

Updated: May 8, 2026

Stimulation of Stem Cell Niches and Tissue Regeneration in Mouse Skin by Switchable Protoporphyrin IX-Dependent Photogeneration of Reactive Oxygen Species In Situ
10:05

Stimulation of Stem Cell Niches and Tissue Regeneration in Mouse Skin by Switchable Protoporphyrin IX-Dependent Photogeneration of Reactive Oxygen Species In Situ

Published on: May 8, 2020

Ingenol mebutate: A novel topical drug for actinic keratosis

Suruchi Aditya1, Sanjeev Gupta

  • 1Department of Pharmacology, Dr Harvansh Singh Judge Institute of Dental Sciences, Sector 25, Chandigarh, India.

Indian Dermatology Online Journal
|August 29, 2013
PubMed

Insights

Ingenol mebutate offers a new, convenient treatment for actinic keratoses (AK), a precursor to skin cancer. This topical therapy, applied over three days, provides a safe and effective alternative to longer-duration treatments.

Area of Science:

  • Dermatology and Oncology
  • Pharmacology

Background:

  • Non-melanoma skin cancer incidence is increasing globally.
  • Actinic keratoses (AK) represent a spectrum of sun damage and a risk factor for squamous cell carcinoma (SCC).
  • There is a need for effective, non-invasive, and tissue-sparing treatments for AK.

Purpose of the Study:

  • To evaluate ingenol mebutate as a novel topical treatment for actinic keratoses (AK).
  • To highlight the chemoablative and immunostimulatory properties of ingenol mebutate.
  • To present ingenol mebutate as a convenient, safe, and effective field therapy option.

Main Methods:

  • Ingenol mebutate, derived from Euphorbia peplus latex, was investigated for its therapeutic potential.
  • Clinical studies assessed the safety and efficacy of ingenol mebutate for AK treatment.
  • The drug's application duration and mechanism of action were examined.

Main Results:

  • Ingenol mebutate demonstrated significant efficacy in treating AK.
  • The drug exhibits both chemoablative and immunostimulatory effects.
  • Clinical studies confirmed its safety and tolerability profile.

Conclusions:

  • Ingenol mebutate is an FDA-approved chemotherapeutic agent for field AK therapy.
  • Its short, three-day application offers a significant advantage over traditional multi-week treatments.
  • Ingenol mebutate provides a convenient, safe, effective, and well-tolerated therapeutic option for AK.
Keywords:
Actinic keratosisingenol mebutatenonmelanoma skin cancer

More Related Videos

Y-27632 Enriches the Yield of Human Melanocytes from Adult Skin Tissues08:06

Y-27632 Enriches the Yield of Human Melanocytes from Adult Skin Tissues

Published on: July 8, 2020

Related Concept Videos

Clinical Applications of Epidermal Stem Cells01:19

Clinical Applications of Epidermal Stem Cells

Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own EpiSCs...
Acne Infection01:27

Acne Infection

Acne is a multifactorial skin condition primarily affecting adolescents and young adults, with a global prevalence estimated to exceed 75% in this demographic. The condition is characterized by the formation of comedones (blackheads and whiteheads), papules, pustules, nodules, and, in severe cases, cysts, particularly in areas rich in sebaceous glands such as the face, neck, chest, and back. The pathogenesis involves increased sebum production, follicular hyperkeratinization, colonization by...
Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.